Long-Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate

Abstract

ZOL maintains bone turnover within the reference range over 24 months from the initiation of treatment. A reduction in the incidence and severity of long-term complications may require persistent normalization of bone turnover over many years, and this now seems a realistic possibility with ZOL.